Hansoh Pharma (03692.HK) Rises Over 4% as Ameile® Gains Fifth Indication and Adjuvant Therapy Study Published in The Lancet Oncology

According to the Zhitong Finance APP, Hansoh Pharma (03692) rose over 4% in the morning session. As of press time, it was up 3.64%, trading at HK$42.12, with a turnover of HK$97.6223 million.

On the news front, on January 8, Hansoh Pharma announced that the group's innovative drug Alebra^®(Hansoh Pharma's Aumetinib Mesylate Tablets) received the drug registration certificate issued by the National Medical Products Administration ("NMPA") of China, approving the addition of "Ameile".^®In combination with pemetrexed and platinum-based chemotherapy, it is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") harboring epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21(L858R) substitution mutations. This is Almonertinib.^®The fifth approved indication.

Notably, according to Hansoh Pharma's official WeChat account, the internationally renowned oncology journal *Lancet Oncology* (Chinese translation: *The Lancet Oncology*, Impact Factor: 35.9) recently published a significant online release about Hansoh Pharma’s innovative drug, Amellet.^®(Latest Research Results of Almonertinib Mesylate Tablets, 110mg, for Adjuvant Treatment of EGFR-Mutant Non-Small Cell Lung Cancer) The data shows that Almonertinib significantly improves disease-free survival (DFS) in patients with completely resected stage II-IIIB EGFR-mutant NSCLC and has a good safety profile.